Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 StudyHuiqiang Huang, Jun Zhu, DocHyun Yoon et al.|Blood|2019Cited by 11
Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: An Open-Label, Single-Arm, Multicenter Phase 2 StudyWon-Seog Kim, Yok‐Lam Kwong, Hyeon‐Seok Eom et al.|Blood|2018Cited by 8